financetom
Business
financetom
/
Business
/
US FDA declines to approve Atara Biotherapeutics' cancer therapy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA declines to approve Atara Biotherapeutics' cancer therapy
Jan 16, 2025 5:55 AM

Jan 16 (Reuters) - The U.S. Food and Drug Administration

on Thursday declined to approve Atara Biotherapeutics' ( ATRA )

cancer therapy, chemically called tabelecleucel.

The company was seeking approval for the therapy to treat

patients with Epstein-Barr virus positive post-transplant

lymphoproliferative disease (EBV+ PTLD).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved